

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
X	<p>T. PEMOVSKA ET AL: "Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia", CANCER DISCOVERY, vol. 3, no. 12, 20 September 2013 (2013-09-20), pages 1416-1429, XP055179364, ISSN: 2159-8274, DOI: 10.1158/2159-8290.CD-13-0350 * p. 1422, middle of left col. * -& T Pemovska ET AL: "Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia - Supplementary Materials", Cancer Discovery, 1 December 2013 (2013-12-01), XP055428597, DOI: 10.1158/2159-8290.CD-13-0350 Retrieved from the Internet: URL:http://cancerdiscovery.aacrjournals.org/content/candisc/suppl/2013/09/18/2159-8290.CD-13-0350.DC1/supp_figs_tables_and_methods.pdf [retrieved on 2017-11-24] * p. 19, Supplementary Table 4 *</p>	1,4-7, 12-15	<p>INV. A61K31/519 A61K31/573 A61K31/454 A61P35/00 A61P35/02 A61K45/06</p>
			<p>TECHNICAL FIELDS SEARCHED (IPC)</p> <p>A61K</p>
X	<p>DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 2013 (2013-11), APPELMANN IRIS ET AL: "Prevention Of Minimal Residual Disease In Ph plus AL", XP002775989, Database accession no. PREV201400360357 * the whole document *</p>	1,4-7, 12-15	
<p>The supplementary search report has been based on the last set of claims valid and available at the start of the search.</p>			
Place of search		Date of completion of the search	Examiner
The Hague		24 November 2017	Scheithe, Rupert
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

1
EPO FORM 1503 03.82 (P04N04)

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
X	US 2014/135350 A1 (NI YONG [US] ET AL) 15 May 2014 (2014-05-15)	1-8, 13-15	
Y	* para. 108, 109, 200-102; Example 3; Comparative Examples A, B *	9-11	
Y	----- PALUMBO A ET AL: "Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma", BLOOD REVIEWS, CHURCHILL LIVINGSTONE, AMSTERDAM, NL, vol. 23, no. 2, 1 March 2009 (2009-03-01), pages 87-93, XP025987063, ISSN: 0268-960X, DOI: 10.1016/J.BLRE.2008.07.003 [retrieved on 2008-09-06] * the whole document *	9-11	
X,P	----- DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; December 2014 (2014-12), CHEN HAIMING ET AL: "Anti-Myeloma Activity by the Combination of the JAK2 Inhibitor Ruxolitinib with Lenalidomide and Corticosteroids", XP002775990, Database accession no. PREV201500279383 * the whole document *	1-15	
	----- -/--		TECHNICAL FIELDS SEARCHED (IPC)
The supplementary search report has been based on the last set of claims valid and available at the start of the search.			
Place of search The Hague		Date of completion of the search 24 November 2017	Examiner Scheithe, Rupert
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

1
EPO FORM 1503 03 82 (P04N04)

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
A	<p>LIU TUOEN ET AL: "Interleukin-6 and JAK2/STAT3 signaling mediate the reversion of dexamethasone resistance after dexamethasone withdrawal in 7TD1 multiple myeloma cells", LEUKEMIA RESEARCH, vol. 37, no. 10, 18 July 2013 (2013-07-18) , pages 1322-1328, XP028710609, ISSN: 0145-2126, DOI: 10.1016/J.LEUKRES.2013.06.026 * p. 1323, left col., last sentence before chapter "2. Materials and methods"; chapter 3.3.; Fig 3 *</p> <p style="text-align: center;">-----</p>	1-15	
			TECHNICAL FIELDS SEARCHED (IPC)
The supplementary search report has been based on the last set of claims valid and available at the start of the search.			
Place of search The Hague		Date of completion of the search 24 November 2017	Examiner Scheithe, Rupert
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			

1
EPO FORM 1503 03 82 (P04N04)

CLAIMS INCURRING FEES

The present European patent application comprised at the time of filing claims for which payment was due.

Only part of the claims have been paid within the prescribed time limit. The present European search report has been drawn up for those claims for which no payment was due and for those claims for which claims fees have been paid, namely claim(s):

No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for those claims for which no payment was due.

LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

see sheet B

All further search fees have been paid within the fixed time limit. The present (supplementary) European search report has been drawn up for all claims.

As all searchable claims could be searched without effort justifying an additional fee, the Search Division did not invite payment of any additional fee.

Only part of the further search fees have been paid within the fixed time limit. The present (supplementary) European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid, namely claims:

None of the further search fees have been paid within the fixed time limit. The present (supplementary) European search report has been drawn up for those parts of the European patent application which relate to the first mentioned in the claims, namely claims:

6(completely); 1-5, 7-15(partially)

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

1. claims: 6(completely); 1-5, 7-15(partially)

A JAK2 inhibitor and a glucocorticoid for use according to claim 1, wherein the JAK2 inhibitor is ruxolitinib.

2. claims: 1-5, 7-15(all partially)

A JAK2 inhibitor and a glucocorticoid for use according to claim 1, wherein the JAK2 inhibitor is fedratinib.

3. claims: 1-5, 7-15(all partially)

A JAK2 inhibitor and a glucocorticoid for use according to claim 1, wherein the JAK2 inhibitor is baricitinib.

4. claims: 1-5, 7-15(all partially)

A JAK2 inhibitor and a glucocorticoid for use according to claim 1, wherein the JAK2 inhibitor is pacritinib.

5. claims: 1-5, 7-15(all partially)

A JAK2 inhibitor and a glucocorticoid for use according to claim 1, wherein the JAK2 inhibitor is AZD1480.

6. claims: 1-5, 7-15(all partially)

A JAK2 inhibitor and a glucocorticoid for use according to claim 1, wherein the JAK2 inhibitor is XL019.

7. claims: 1-5, 7-15(all partially)

A JAK2 inhibitor and a glucocorticoid for use according to claim 1, wherein the JAK2 inhibitor is LY2784544.

8. claims: 1-5, 7-15(all partially)

A JAK2 inhibitor and a glucocorticoid for use according to claim 1, wherein the JAK2 inhibitor is BMS-911543.

9. claims: 1-5, 7-15(all partially)

A JAK2 inhibitor and a glucocorticoid for use according to

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

claim 1, wherein the JAK2 inhibitor is NS-018.

10. claims: 1-5, 7-15(all partially)

A JAK2 inhibitor and a glucocorticoid for use according to claim 1, wherein the JAK2 inhibitor is CYT387.

11. claims: 1-5, 7-15(all partially)

A JAK2 inhibitor and a glucocorticoid for use according to claim 1, wherein the JAK2 inhibitor is atiprimod dihydrochloride.

12. claims: 1-5, 7-15(all partially)

A JAK2 inhibitor and a glucocorticoid for use according to claim 1, wherein the JAK2 inhibitor is CP 690550.

13. claims: 1-5, 7-15(all partially)

A JAK2 inhibitor and a glucocorticoid for use according to claim 1, wherein the JAK2 inhibitor is Cucurbitacin I.

14. claims: 1-5, 7-15(all partially)

A JAK2 inhibitor and a glucocorticoid for use according to claim 1, wherein the JAK2 inhibitor is 1,2,3,4,5,6-Hexabromocyclohexane.

15. claims: 1-5, 7-15(all partially)

A JAK2 inhibitor and a glucocorticoid for use according to claim 1, wherein the JAK2 inhibitor is Lestaurtinib.

16. claims: 1-5, 7-15(all partially)

A JAK2 inhibitor and a glucocorticoid for use according to claim 1, wherein the JAK2 inhibitor is NSC 33994.

17. claims: 1-5, 7-15(all partially)

A JAK2 inhibitor and a glucocorticoid for use according to claim 1, wherein the JAK2 inhibitor is SD 1008.

**LACK OF UNITY OF INVENTION
SHEET B**

Application Number
EP 15 80 0211

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 15 80 0211

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

24-11-2017

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2014135350 A1	15-05-2014	AR 093490 A1	10-06-2015
		AU 2013344780 A1	28-05-2015
		CA 2890755 A1	22-05-2014
		CL 2015001286 A1	28-08-2015
		CN 105007901 A	28-10-2015
		CR 20150265 A	24-08-2015
		EA 201590930 A1	31-08-2015
		EP 2919766 A1	23-09-2015
		HK 1213796 A1	15-07-2016
		JP 2015537030 A	24-12-2015
		KR 20150085833 A	24-07-2015
		PE 11572015 A1	19-08-2015
		PH 12015501089 A1	27-07-2015
		SG 10201703685U A	29-06-2017
		SG 11201503695X A	29-06-2015
		TW 201434496 A	16-09-2014
		US 2014135350 A1	15-05-2014
		WO 2014078486 A1	22-05-2014
